Cargando…

Confronting TB/HIV in the era of increasing anti-TB drug resistance

HIV associated TB is a major public health problem. In 2006, it was estimated that there were over 700,000 people who suffered from HIV associated TB, of whom about 200, 000 have died. The burden of HIV associated TB is greatest in Sub-Saharan Africa where the TB epidemic is primarily driven by HIV....

Descripción completa

Detalles Bibliográficos
Autores principales: Chakaya, Jeremiah, Getahun, Haileyesus, Granich, Reuben, Havlir, Diane
Formato: Texto
Lenguaje:English
Publicado: The International AIDS Society 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2588552/
https://www.ncbi.nlm.nih.gov/pubmed/19014421
http://dx.doi.org/10.1186/1758-2652-11-6
_version_ 1782160950064840704
author Chakaya, Jeremiah
Getahun, Haileyesus
Granich, Reuben
Havlir, Diane
author_facet Chakaya, Jeremiah
Getahun, Haileyesus
Granich, Reuben
Havlir, Diane
author_sort Chakaya, Jeremiah
collection PubMed
description HIV associated TB is a major public health problem. In 2006, it was estimated that there were over 700,000 people who suffered from HIV associated TB, of whom about 200, 000 have died. The burden of HIV associated TB is greatest in Sub-Saharan Africa where the TB epidemic is primarily driven by HIV. There has been steady progress made in reducing the burden of HIV in TB patients with an increasing number of TB patients tested for HIV and provided with cotrimoxazole preventive therapy (CPT) and anti-retroviral treatment (ART). Less progress is being made to reduce the burden of TB in people living with HIV. The number of HIV infected persons reported to have been screened for TB was less than 1% while Isoniazid preventive therapy was reported to have been provided to less than 0.1% of eligible persons in 2006. A major push is urgently needed to accelerate the implementation of three important interventions. The three are Intensified TB Screening (ICF) among people living with HIV, the provision of Isoniazid Preventive Therapy (IPT) and TB Infection Control(IC). These interventions are best carried out by HIV control programmes which should therefore be encouraged to take greater responsibility in implementing these interventions.
format Text
id pubmed-2588552
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher The International AIDS Society
record_format MEDLINE/PubMed
spelling pubmed-25885522008-11-28 Confronting TB/HIV in the era of increasing anti-TB drug resistance Chakaya, Jeremiah Getahun, Haileyesus Granich, Reuben Havlir, Diane J Int AIDS Soc Review HIV associated TB is a major public health problem. In 2006, it was estimated that there were over 700,000 people who suffered from HIV associated TB, of whom about 200, 000 have died. The burden of HIV associated TB is greatest in Sub-Saharan Africa where the TB epidemic is primarily driven by HIV. There has been steady progress made in reducing the burden of HIV in TB patients with an increasing number of TB patients tested for HIV and provided with cotrimoxazole preventive therapy (CPT) and anti-retroviral treatment (ART). Less progress is being made to reduce the burden of TB in people living with HIV. The number of HIV infected persons reported to have been screened for TB was less than 1% while Isoniazid preventive therapy was reported to have been provided to less than 0.1% of eligible persons in 2006. A major push is urgently needed to accelerate the implementation of three important interventions. The three are Intensified TB Screening (ICF) among people living with HIV, the provision of Isoniazid Preventive Therapy (IPT) and TB Infection Control(IC). These interventions are best carried out by HIV control programmes which should therefore be encouraged to take greater responsibility in implementing these interventions. The International AIDS Society 2008-11-06 /pmc/articles/PMC2588552/ /pubmed/19014421 http://dx.doi.org/10.1186/1758-2652-11-6 Text en Copyright ©2008 Chakaya et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Chakaya, Jeremiah
Getahun, Haileyesus
Granich, Reuben
Havlir, Diane
Confronting TB/HIV in the era of increasing anti-TB drug resistance
title Confronting TB/HIV in the era of increasing anti-TB drug resistance
title_full Confronting TB/HIV in the era of increasing anti-TB drug resistance
title_fullStr Confronting TB/HIV in the era of increasing anti-TB drug resistance
title_full_unstemmed Confronting TB/HIV in the era of increasing anti-TB drug resistance
title_short Confronting TB/HIV in the era of increasing anti-TB drug resistance
title_sort confronting tb/hiv in the era of increasing anti-tb drug resistance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2588552/
https://www.ncbi.nlm.nih.gov/pubmed/19014421
http://dx.doi.org/10.1186/1758-2652-11-6
work_keys_str_mv AT chakayajeremiah confrontingtbhivintheeraofincreasingantitbdrugresistance
AT getahunhaileyesus confrontingtbhivintheeraofincreasingantitbdrugresistance
AT granichreuben confrontingtbhivintheeraofincreasingantitbdrugresistance
AT havlirdiane confrontingtbhivintheeraofincreasingantitbdrugresistance